1月8日,罗氏(Roche)宣布与宜联生物达成一项最高达5.7亿美元的授权许可协议,获得后者靶向B7H3的ADC tambotatug pelitecan(YL201)中国以外地区的全球独家权益。这一交易是罗氏2025年以来第三笔ADC重磅合作,也是与宜联生物双方不到两年内第二次携手。罗氏加倍投入小细胞肺癌(SCLC)的抗体药物偶联物(ADC)研发,再次与现有合作伙伴宜联生物(MediLink ...
Source Link1月8日,罗氏(Roche)宣布与宜联生物达成一项最高达5.7亿美元的授权许可协议,获得后者靶向B7H3的ADC tambotatug pelitecan(YL201)中国以外地区的全球独家权益。这一交易是罗氏2025年以来第三笔ADC重磅合作,也是与宜联生物双方不到两年内第二次携手。罗氏加倍投入小细胞肺癌(SCLC)的抗体药物偶联物(ADC)研发,再次与现有合作伙伴宜联生物(MediLink ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.